Dr. Orgel is currently an attending physician on the Medical Supportive Care/Survivorship and Supportive Care Program and the Leukemia and Lymphoma Team within the Division of pediatric Hematology, Oncology, and Blood & Marrow Transplantation at the Children's Hospital Los Angeles (Los Angeles, CA). Dr. Orgel's clinical specialty focuses on higher risk and rare malignant hematology, and specifically, the rare phenomenon of Mixed-Phenotype Acute Leukemia (MPAL). He possesses an academic appointment as an Assistant Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) following strong training in general pediatrics from Children's National Medical Center (Washington, DC) and a pediatric hematology/oncology fellowship at CHLA. This was complemented with didactic clinical trial training via completing a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.
Dr. Orgel's primary research interest lies in the field of medical supportive care or "cancer control" (reducing acute and late treatment-related toxicities). His specific focus utilizes a translational research approach to target specific toxic effects to widen therapeutic windows for common chemotherapies and/or improve the quality of life of children with cancer. Currently, Dr. Orgel's active research encompasses studying new agents and novel strategies to reduce hearing loss from chemotherapy (cisplatin), to target obesity in pediatric ALL to improve survival, quality of life, and bone health, and to evaluate resistance to asparaginase (a highly-effective chemotherapy agent) in children with relapsed ALL.
Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 Nov; 63(11):1943-8. View in: PubMed
Orgel E, Mueske NM, Wren TA, Gilsanz V, Butturini AM, Freyer DR, Mittelman SD. Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016 Apr; 85:131-7. View in: PubMed
Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016 Mar; 103(3):808-17. View in: PubMed
Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, Counts PA, Murphy D, Dhall G, Freyer DR. Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. Pediatr Blood Cancer. 2015 Nov 3. View in: PubMed
Felsenstein S, Orgel E, Rushing T, Fu C, Hoffman JA. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J. 2015 Apr; 34(4):e78-84. View in: PubMed
Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H, Mittelman SD. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014 Dec 18; 124(26):3932-8. View in: PubMed
Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, Freyer DR. Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2014 May 1; 32(13):1331-7. View in: PubMed
Orgel E, Ji L, Pastor W, Schore RJ. Infectious morbidity by catheter type in neutropenic children with cancer. Pediatr Infect Dis J. 2014 Mar; 33(3):263-6. View in: PubMed
Orgel E, Rushing T. Efficacy and tolerability of intravenous pentamidine isethionate for pneumocystis jiroveci prophylaxis in a pediatric oncology population. Pediatr Infect Dis J. 2014 Mar; 33(3):319-21. View in: PubMed
Orgel E, Zung L, Ji L, Finklestein J, Feusner J, Freyer DR. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer. 2013 Sep; 60(9):1528-33. View in: PubMed
Orgel E, Mittelman SD. The links between insulin resistance, diabetes, and cancer. Curr Diab Rep. 2013 Apr; 13(2):213-22. View in: PubMed
Murphy D, Orgel E, Termuhlen A, Shannon S, Warren K, Quinn GP. Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late! Front Oncol. 2013; 3:248. View in: PubMed
Orgel E, Jain S, Ji L, Pollick L, Si S, Finlay J, Freyer DR. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer. 2012 Jun; 58(6):953-8. View in: PubMed
Orgel E, McCarter R, Jacobs S. A failing medical educational model: a self-assessment by physicians at all levels of training of ability and comfort to deliver bad news. J Palliat Med. 2010 Jun; 13(6):677-83. View in: PubMed